Benzinga | Aug 5, 2021 04:00PM EDT

Arrowhead Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $45.89M Beat $37.52M Estimate

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 123.08 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $45.89 million which beat the analyst consensus estimate of $37.52 million by 22.31 percent. This is a 67.63 percent increase over sales of $27.38 million the same period last year.